Krishnaprasad Gajaraj, Associate Vice President at Avalon Consulting, shares his perspective in “Chemical Industry Digest” on India’s emerging opportunity in complex molecules and the strategic signals extending beyond the current GLP-1 momentum. The article highlights areas such as imported APIs, peptide reagents, sterile fill-finish, green chemistry and next-generation therapies as potential avenues for industry growth.
As global pharmaceutical supply chains evolve, India has an opportunity to strengthen its position across higher-value segments, supported by capabilities in manufacturing, technology and innovation. For business leaders, understanding these emerging opportunities will be critical to shaping investment priorities and building sustainable growth in the evolving pharmaceutical landscape.
Loading...
Reload document
Open in new tab 
